Trials / Conditions / Macrophage Activation Syndrome

Macrophage Activation Syndrome

14 registered clinical trials studyying Macrophage Activation Syndrome — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE St NCT06339177	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	Assessment of Macrophage Activation syndromE in STill's Disease NCT06405152	Swedish Orphan Biovitrum	—
Active Not Recruiting	Anakinra in Dengue With Hyperinflammation ( AnaDen ) NCT05611710	Oxford University Clinical Research Unit, Vietnam	Phase 2
Unknown	Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome NCT05137496	Beijing Friendship Hospital	Phase 3
Completed	Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's NCT05001737	Swedish Orphan Biovitrum	Phase 3
Completed	Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction NCT04339712	Hellenic Institute for the Study of Sepsis	Phase 2
Completed	Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bact NCT03721809	University Hospital, Rouen	N/A
Active Not Recruiting	Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults NCT03827343	National Cancer Institute (NCI)	—
Completed	A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic NCT03311854	Swedish Orphan Biovitrum	Phase 2
Completed	A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis NCT03332225	Hellenic Institute for the Study of Sepsis	Phase 2
Terminated	Treatment of Macrophage Activation Syndrome (MAS) With Anakinra NCT02780583	University of Alabama at Birmingham	Phase 1
Unknown	Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） NCT02569463	Peking University People's Hospital	Phase 1 / Phase 2
Active Not Recruiting	CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation NCT01966367	Diane George	Phase 1 / Phase 2
Unknown	New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome NCT01095146	Amrita Institute of Medical Sciences & Research Center	—